K-ras, p53 mutations, and microsatellite instability (MSI) in gallbladder cancer

Journal of Surgical Oncology

Volumn 93, Issue 8, 2006, Pages 644-649

  Saetta, Angelica A ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

K ras mutations; Microsatellite instability; Molecular pathogenesis of gallbladder cancer; p53 alterations

Indexed keywords

PROTEIN P53;

CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CONFERENCE PAPER; DIGESTIVE SYSTEM CANCER; GALLBLADDER CANCER; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; ONCOGENE K RAS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 33744953215     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20532     Document Type: Conference Paper

References (63)

1. Pitt HA, Dooley WC, Yeo CJ, et al.: Malignancies of the biliary tree. Curr Prob Surg 1995;32:1-90.
2. Silverberg E, Lubera JA: Cancer Statistics 1989. CA-Cancer J Clin 1989;39:3-20.
3. Dowling PG, Kelly KJ: The histogenesis of adenocarcinoma of the gallbladder. Cancer 1986;58:1702-1708.
4. Chianale J, del Pino G, Nervi F, et al.: Increasing gallbladder cancer mortality during the last decade in Chile, a high risk area. Int J Cancer 1990;46:1131-1133.
5. Lazcano-Ponce EC, Miquel JF, Munoz N, et al.: Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001;51:349-364. Review.
6. Itoi T, Watanabe H, Ajioka Y, et al.: APC, K-ras codon 12 mutations and p53 gene expression in carcinoma and adenoma of the gall-bladder suggest two genetic pathways in gall-bladder carcinogenesis. Pathol Int 1996;46:333-340.
7. Kimura K, Ohio M, Saisho H, et al.: Association of gallbladder carcinoma and anomalous pancreaticobiliary ductal union. Gastroenterology 1985;89:1258-1265.
8. Mon K, Akimoto R, Kanno M, et al.: Anomalous union of the pancreaticobiliary ductal system without dilation of the common bile duct or tumor: Case reports and literature review. Hepatogastroenterology 1999;46:142-147.
9. Hanada K, Itoh M, Fujii K, et al.: K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer 1996;77:452-480.
10. Masuhara S, Kasuya K, Aoki T, et al.: Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 2000;7:198-205.
11. Matsubara T, Funabiki T, Jinno O, et al.: p53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. J Hepatobiliary Pancreat Surg 1999;6:286-293.
12. Mu DQ, Peng YS, Xu QJ, et al.: Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 2004;10:471-475. Review.
13. Burmer GC, Loeb LA: Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA 1989;86:2403-2407.
14. Rashid A, Ueki T, Gao YT, et al.: K-ras mutation, p53 over-expression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 2002;8: 3156-3163.
15. Wistuba II, Sugio K, Hung J, et al.: Allele-specific mutations involved in the pathogenesis of endermic gallbladder carcinoma in Chile. Cancer Res 1995;55:2511-2515.
16. Singh MK, Chetri K, Pandey UB, et al.: Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol 2004;19:916-921.
17. Imai M, Hoshi T, Ogawa K, et al.: K-ras codon 12 mutations in biliary tract tumors detected by polymerase chain reaction denaturing gradient gel electrophoresis. Cancer 1994;73:2727-2733.
18. Watanabe M, Asaka M, Tanaka J, et al.: Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroenterology 1994;107:1147-1153.
19. Malats N, Porta M, Pinol JL, et al.: Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer. PANK-ras I Project Investigators. J Clin Oncol 1995;13:1679-1686.
20. Tanno S, Obara T, Maguchi H, et al.: Association between anomalous pancreaticobiliary ductal union and adenomyomatosis of the gall-bladder. J Gastroenterol Hepatol 1998;13:175-180.
21. Hanada K, Tsuchida A, Iwao T, et al.: Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999;94:1638-1642.
22. Watanabe H, Date K, Itoi T, et al.: Histological and genetic changes in malignant transformation of gallbladder adenoma. Ann Oncol 1999;10:136-139.
23. Kim YT, Kim J, Jang YH, et al.: Genetic alterations in gallbladder adenoma, dysplasia and carcinoma. Cancer Lett 2001;169:59-68.
24. Kohya N, Kitajima Y, Kitahara K, et al.: Mutation analysis of K-ras and beta-catenin genes related to O6-methylguanin-DNA methyltransferase and mismatch repair protein status in human gallbladder carcinoma. Int J Mol Med 2003;11:65-69.
25. Tada M, Yokosuka O, Omata M, et al.: Analysis of ras gene mutations in biliary and pancreatic tumors by polymerase chain reaction and direct sequencing. Cancer 1990;66:930-935.
26. Wistuba II, Miquel JF, Gazdar AF, et al.: Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999;30:21-25.
27. Tanno S, Obara T, Fujii T, et al.: Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer 1998;83:267-275.
28. Ajiki T, Fujimori T, Onoyama H, et al.: K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut 1996;38:426-429.
29. Saetta A, Lazaris AC, Davaris PS, et al.: Detection of ras oncogene point mutations and simultaneous proliferative fraction estimation in gallbladder cancer. Pathol Res Pract 1996;192:532-540.
30. Hanada K, Tsuchida A, Iwao T, et al.: Gene mutations of K-ras in gallbladder mucosae and gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Am J Gastroenterol 1999;94:1638-1642.
31. Curtin K, Slattery ML, Holubkov R, et al.: p53 alterations in colon tumors: A comparison of SSCP/sequencing and immunohistochemistry. Appl Immunohistochem Mol Morphol 2004;12:380-386.
32. Itoi T, Watanabe H, Yoshida M, et al.: Correlation of p53 protein expression with gene mutation in gall-bladder carcinomas. Pathol Int 1997;47:525-530.
33. Parwani AV, Geradts J, Caspers E, et al.: Immunohistochemical and genetic analysis of non-small cell and small cell gallbladder carcinoma and their precursor lesions. Mod Pathol 2003;16:299-308.
34. Kalekou H, Miliaras D: Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma. J Gastroenterol Hepatol 2004;19:812-818.
35. Da Rocha AO, Coutinho LM, Scholl JG, et al.: The value of p53 protein expression in gallbladder carcinoma: Analysis of 60 cases. Hepatogastroenterology 2004;51:1310-1314.
36. Chuang SC, Lee KT, Tsai KB, et al.: Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg 2004;28:995-1000.
37. Wistuba I, Gazdar AF, Roa I, et al.: Albores-Saavedra p53 protein overexpression in gallbladder carcinoma and its precursor lesions: An immunohistochemical study. Human Pathol 1996;27;360-365.
38. Yokoyama N, Hitomi J, Watanabe H, et al.: Mulations of p53 in gallbladder carcinomas in high-incidence areas of Japan and Chile. Cancer Epidemiol Biomarkers Prev 1998;7:297-301.
39. Puhalla H, Kandioler D, Ludwig C, et al.: Gruenberger Tp53 analysis in gallbladder cancer: Comparison of gene analysis versus immunohistochemistry. Anticancer Res 2004;24:1201-1206.
40. Fujii K, Yokozaki H, Yasui W, et al.: High frequency of p53 mutation in adenocarcinomas of the gallbladder. Cancer Epidemiol Biomarkers Prev 1996;5:461-466.
41. Hanada K, Itoh M, Fujii K, et al.: TP53 mutations in stage 1 gallbladder carcinoma wilh special attention to growth patterns. Eur J Cancer 1997;33:1136-1140.
42. Nagai M, Watanaba M, Iwase T, et al.: Clinical and genetic analysis of noncancerous and cancerous biliary epithelium in patients with pancreaticobiliary malfunction. World J Surg 2002;26:91-98.
43. Ku JL, Yoon KA, Kim IJ, et al.: Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer 2002;87:187-193.
44. Ajiki T, Onoyama H, Yamamoto M, et al.: p53 protein expression and prognosis in gallbladder carcinoma and premalignant lesions. Hepatogastroenterology 1996;43:521-526.
45. Saetta A, Lazaris AC, Michalopoulos NV, et al.: Genetic alterations involved in the development of gallbladder carcinomas from Greek patients. Hepatogastroenterology 2001;48:1284-1288.
46. Saetta A, Koilakou SV, Michalopoulos NV, et al.: Evaluation of BAT-26 as an indicator of microsatellite instability in gallbladder carcinomas. Hepatogastroenterology 2003;50:1799-802.
47. Lee HS, Choi SI, Lee HK, et al.: Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol 2002;15:632-640.
48. Lawes DA, SenGupta S, Boulos PB, et al.: The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur J Surg Oncol 2003;29:201-212.
49. Parsons R, Myerhoff LL, Liu B, et al: Microsatellite instability and mutations of the transforming growth factor-β type 11 receptor gene in colorectal cancer. Cancer Res 1995;55:5548-5550.
50. Ku JL, Yoon KA, Kim DY, et al.: Mutations in hMSH6 alone are not sufficient to cause the microsatellite insuibility in colorectal cancer cell lines. Eur J Cancer 1999;35:1724-1729.
51. Calin GA, Gafa R, Tibiletti MG, et al.: Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFHR and BLM genes. Int J Cancer 2000;89:230-235.
52. Furlan D, Casati B, Cerutti R, et al.: Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J Pathol 2002;197:603-609.
53. Chang HJ, Kim SW, Kim YT, et al.: Loss of heterozygosity in dysplasia and carcinoma of the gallbladder. Modern Pathol 1999;12:763-769.
54. Umar A, Boland CR, Terdiman JP, et al: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
55. Boland CR, Thibodeau SN, Hamilton SR, et al.: A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
56. Saito K, Yeaton P, Sato J, et al.: Genetic mechanisms of tumorigenesis in cholangiocarcinoma and gallbladder carcinoma (abstract). Hepatology 1995;22:110 (Abstract).
57. Sessa F, Furlan D, Genasetti A, et al.: Microsatellite instability and p53 expression in gallbladder carcinomas. Diagn Mol Pathol 2003;12:96-102.
58. Yoshida T, Sugai T, Habano W, et al.: Microsatellite instability in gallbladder carcinoma: Two independent genetic pathways of gallbladder carcinogenesis. J Gastroenterol 2000;35:768-774.
59. Saetta AA, Gigelou F, Papanastasiou PI, et al.: High-level microsatellite instability is not involved in gallbladder carcinogenesis. Exp Mol Pathol 2006;80:67-71.
60. Roa JC, Roa I, Correa P, et al.: Microsatellite instability in preneoplastic and neoplastic lesions of the gallbladder. J Gastroenterol 2005;40:79-86.
61. Hiduka E, Yanagisawa A, Sakai Y, et al.: Losses of heterozygosity on chromosomes 17p and 9p/18q may play important roles in early and advanced phases of gallbladder carcinogenesis. J Cancer Res Clin Oncol 1999;125:439-443.
62. Wistuba H, Tang M, Maitra A, et al.: Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001;61:3795-800.
63. Matsuo K, Kuroki T, Kitaoka F, et al.: Loss of heterozygosity of chromosome 16q in gallbladder carcinoma. J Surg Res 2002;102:133-136.